Nanomix, Inc, is a development stage company that seeks to develop, manufacture, and commercialize point-of-care diagnostic tests that are used to detect or monitor diseases. The Company’s product development efforts are focused on our proprietary technology, a novel point-of-care diagnostic platform that offers certain customer advantages as compared to other point-of-care diagnostic technologies. Nanomix, Inc. was originally formed in 2001 as a nanotechnology sensor company. In 2009, ownership changed, and the business was redirected to development and commercialization of a mobile point-of-care diagnostic platform.
Company profile
Ticker
NNMX, NNMXD
Exchange
Website
CEO
Carl W. Rausch
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
AVANYX Therapeutics, Inc., Boston Therapeutics, Inc.
SEC CIK
Corporate docs
Subsidiaries
Nanomix, Inc. • CurDM Group Holdings LLC ...
IRS number
270801073
NNMX stock data
Latest filings (excl ownership)
8-K
Departure of Directors or Certain Officers
24 Nov 23
NT 10-Q
Notice of late quarterly filing
15 May 23
10-K
2022 FY
Annual report
7 Apr 23
NT 10-K
Notice of late annual filing
31 Mar 23
8-K
Regulation FD Disclosure
10 Mar 23
8-K
Nanomix Appoints Finance Veteran Chris Hetterly as Chief Financial Officer
25 Jan 23
10-Q
2022 Q3
Quarterly report
14 Nov 22
8-K
Unregistered Sales of Equity Securities
10 Nov 22
8-K
Nanomix Appoints Industry Veteran Tadd S. Lazarus, M.D., to the Board of Directors
9 Sep 22
10-Q
2022 Q2
Quarterly report
15 Aug 22
Latest ownership filings
SC 13G/A
Hudson Bay Capital Management LP
6 Feb 24
SC 13G/A
Hudson Bay Capital Management LP
10 Feb 23
3
Chris Hetterly
26 Jan 23
4
GREGORY T SCHIFFMAN
21 Dec 22
3
GREGORY T SCHIFFMAN
21 Dec 22
4
GARRETT GRUENER
19 Dec 22
3
Vidur Sahney
19 Dec 22
3
John Hardesky
19 Dec 22
3
Vidur Sahney
16 Dec 22
4
DAVID LUDVIGSON
16 Dec 22
Financial summary
Quarter (USD) | Dec 22 | Sep 22 | Jun 22 | Mar 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 17.11 k | 17.11 k | 17.11 k | 17.11 k | 17.11 k | |
Cash burn (monthly) | (no burn) | 1.01 mm | 1.02 mm | 599.78 k | 507.17 k | |
Cash used (since last report) | n/a | 15.02 mm | 15.28 mm | 8.95 mm | 7.57 mm | |
Cash remaining | n/a | -15.00 mm | -15.27 mm | -8.93 mm | -7.55 mm | |
Runway (months of cash) | n/a | -14.9 | -14.9 | -14.9 | -14.9 |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
30 Nov 22 | David Ludvigson | Common Stock | Acquire X | No | No | 0.058 | 42,195 | 2.45 k | 1,695,176 | |
30 Nov 22 | David Ludvigson | Incentive Stock Option Common Stock | Dispose X | No | No | 0.058 | 42,195 | 2.45 k | 1,695,176 |